Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;36(1):e24145.
doi: 10.1002/jcla.24145. Epub 2021 Dec 21.

The expression and clinical significance of CD59 and FLAER in Chinese adult AML patients

Lijuan Li  1 , Shunjie Yu  1 , Shanshan Liu  1 , Fanqiao Meng  1 , Xiaotong Ren  1 , Zhaoyun Liu  1 , Rong Fu  1
Affiliations

The expression and clinical significance of CD59 and FLAER in Chinese adult AML patients

Lijuan Li et al. J Clin Lab Anal. 2022 Jan.

Abstract

Background: The role of CD59 and fluorescently labeled aerolysin (FLAER) in acute myeloid leukemia (AML) remains unclear and requires further investigation. To explore the relationship between CD59, FLAER, and AML, we investigated CD59 and FLAER expression in AML and analyzed their relationship with clinical characteristics of AML patients.

Methods: We employed flow cytometry (FCM) to analyze CD59 and FLAER expression in 161 AML patients at Tianjin Medical University General Hospital and evaluated its association with sex, white blood cell (WBC) count, platelet (PLT) count, thrombin time (TT), prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), D-Dimer(D-D), and lactate dehydrogenase (LDH), followed by analyzing its connection with disease progression and complete remission (CR).

Results: CD59 and FLAER deficiencies were identified in AML patients. Compared with CR group, non-CR group patients revealed more CD59 and FLAER deficiency. Compared with non-acute promyelocytic leukemia (M3) group, M3 group patients had more CD59 and FLAER deficiency. CD59- level in primordial cells of M3 patients was positively correlated with primordial cell ratio (r = 0.660, p = 0.003). Additionally, we discovered that the decline in CD59 and FLAER levels might be linked to higher D-D and LDH in AML patients. The difference was statistically significant (p < 0.05).

Conclusions: We demonstrated that the decline in CD59 and FLAER levels was associated with leukemia cell proliferation and abnormal coagulation function in AML, suggesting that they could serve as a predictor of AML coagulation dysfunction, particularly in M3.

Keywords: CD59; FLAER; acute myeloid leukemia; coagulation function.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Decline of CD59 and FLAER is low in PB of non‐M3 patients. (A) An example of a flow diagram for FLAER and CD59 analysis in non‐M3. All experiments were performed three times. Scatter plot of FLAER− (B) and CD59− (C) percent of PB samples in 101 non‐M3 patients (35 patients in CR group and 66 patients in newly diagnosed group). PC, primordial cell; MC, monocytes; GC, granulocytes. MC and PC were analyzed in CR group; PC was analyzed in the newly diagnosed group
FIGURE 2
FIGURE 2
Decline of CD59 and FLAER is low in PB of M3 CR group patients. (A) An example of a flow diagram for FLAER and CD59 analysis in M3 CR group. All experiments were conducted three times. Scatter plot of CD59− (B) and FLAER− (C) percent of PB samples in 60 M3 patients (42 CR group patients). PC, primordial cell; MC, monocytes; GC, granulocytes. MC and PC were analyzed in CR group; PC was analyzed in the newly diagnosed group
FIGURE 3
FIGURE 3
Decline of CD59 and FLAER is high in PB of AML patients. An example of a flow diagram for FLAER and CD59 analysis in M3 (A) and non‐M3 (B). All experiments were performed three times. Scatter plot of CD59− (C) and FLAER− (D) percent in 84 AML patients
See this image and copyright information in PMC

References

    1. Garcia‐Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol. 2011;29(5):516‐523. - PMC - PubMed
    1. Garcia‐Manero G. Myelodysplastic syndromes: 2015 update on diagnosis, risk‐stratification and management. Am J Hematol. 2015;90(9):831‐841. - PubMed
    1. Nimer SD. Myelodysplastic syndromes. Blood. 2008;111(10):4841‐4851. - PubMed
    1. Jabbour E, Takahashi K, Wang X, et al. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower‐risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013;88(10):831‐837. - PMC - PubMed
    1. Steensma DP. Myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2015;90(7):969‐983. - PubMed

MeSH terms